СОВРЕМЕННЫЕ ПОДХОДЫ К ДИАГНОСТИКЕ, ПРОБЛЕМЕ КЛИНИЧЕСКОГО ПОЛИМОРФИЗМА НЕЙРОФИБРОМАТОЗА У ДЕТЕЙ (ОБЗОР ЛИТЕРАТУРЫ)
Ключевые слова:
нейрофиброматоз, дети, клинический полиморфизм, диагностикаАннотация
В данной статье проанализировали литературные сведения об особенностях развития нейрофиброматоза у детей. Анализ изученной научно-медицинской литературы показал, что остается много неразрешенных задач, таких как внедрение в клинику эффективных фармакологических препаратов, выявление причин высокой мутабельности гена NF1 и выраженного клинического полиморфизма, трудности в диагностике данной патологии на генетическом уровне. Концентрация основных направлений в исследовании молекулярных механизмов заболевания позволит правильно ориентировать поиск на разрешение сложившихся противоречий.
Библиографические ссылки
Anderson M. K. [и др.]. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas // The Annals of pharmacotherapy. 2022. № 6 (56). C. 716–726.
Armstrong A. E. [и др.]. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas // BMC Cancer. 2023. Т. 23. № 1.
Armstrong A. E. [и др.]. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas // BMC Cancer. 2023. № 1 (23).
Azizi A. A. [и др.]. Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas // Neuro-Oncology Practice. 2024.
Beert E. [и др.]. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors // Genes, chromosomes & cancer. 2011. № 12 (50). C. 1021–1032.
Ben-Shachar S. [и др.]. Predicting neurofibromatosis type 1 risk among children with isolated café-au-lait macules // Journal of the American Academy of Dermatology. 2017. № 6 (76). C. 1077-1083.e3.
Bergqvist C. [и др.]. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966 // Orphanet Journal of Rare Diseases. 2020. Т. 15. № 1.
Boyd K. P., Korf B. R., Theos A. Neurofibromatosis type 1 // Journal of the American Academy of Dermatology. 2009. Т. 61. № 1. C. 1–14.
Bruce R Korf M. P. M. L. M. M. L. K. M. M. Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis. 2025.
Bruce R Korf M. P. M. L. M. M. L. K. M. M. Neurofibromatosis type 1 (NF1): Management and prognosis. 2025.
Carton C. [и др.]. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1 // eClinicalMedicine. 2023.(56). C. 101818.
Chen J. L. [и др.]. Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk // Annual Review of Genomics and Human Genetics. 2022. Т. 23. C. 331–361.
Gross A. M. [и др.]. Selumetinib in Children with Inoperable Plexiform Neurofibromas // New England Journal of Medicine. 2020. № 15 (382). C. 1430–1442.
Gross A. M. [и др.]. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas // Neuro-Oncology. 2023. № 10 (25). C. 1883–1894.
Gutmann D. H. [и др.]. Neurofibromatosis type 1 // Nature reviews. Disease primers. 2017. (3).
Hsu C. K. [и др.]. The Number of Surgical Interventions and Specialists Involved in the Management of Patients with Neurofibromatosis Type I: A 25-Year Analysis // Journal of Personalized Medicine. 2022. № 4 (12).
Legius E. [и др.]. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation // Genetics in Medicine. 2021. № 8 (23). C. 1506–1513.
Legius E. [и др.]. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation // Genetics in Medicine. 2021. № 8 (23). C. 1506–1513.
Legius E., Brems H. Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism // Child’s Nervous System. 2020. № 10 (36). C. 2285–2295.
Mautner V. F. [и др.]. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1 // Neuro-Oncology. 2008. № 4 (10). C. 593.
Nunley K. S. [и др.]. Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1 // Archives of Dermatology. 2009. № 8 (145). C. 883–887.
Pietro S. Di [и др.]. Magnetic Resonance Imaging of Central Nervous System Manifestations of Type 1 Neurofibromatosis: Pictorial Review and Retrospective Study of Their Frequency in a Cohort of Patients // Journal of Clinical Medicine. 2024. № 11 (13).
Pimentel M. F. [и др.]. Prevalence of Choroidal Abnormalities and Lisch Nodules in Children Meeting Clinical and Molecular Diagnosis of Neurofibromatosis Type 1 // Translational Vision Science & Technology. 2022. № 2 (11). C. 10–10.
Prudner B. C. [и др.]. Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives // Neuro-oncology advances. 2019. № Suppl 1 (2). C. I40–I49.
Tang Y., Gutmann D. H. Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects // Cancer management and research. 2023. (15). C. 667–681.
Uusitalo E. [и др.]. Incidence and mortality of neurofibromatosis: A total population study in Finland // Journal of Investigative Dermatology. 2015. № 3 (135). C. 904–906.
Нейрофиброматоз 1 типа (НФ1): Российские клинические рекомендации. 2023.
